首页 | 官方网站   微博 | 高级检索  
     

不同规格布地奈德/福莫特罗吸入剂治疗哮喘的经济学与装置依从性评价
引用本文:秦琼,宋伟华,雷伟,龚银华,缪丽燕,包健安,顾宝晨,陈蓉.不同规格布地奈德/福莫特罗吸入剂治疗哮喘的经济学与装置依从性评价[J].中国医院药学杂志,2016,36(24):2202-2205.
作者姓名:秦琼  宋伟华  雷伟  龚银华  缪丽燕  包健安  顾宝晨  陈蓉
作者单位:1. 苏州大学附属第一医院药学部, 江苏 苏州 215006; 2. 苏州大学附属第一医院呼吸内科, 江苏 苏州 215006
基金项目:国家自然科学基金资助项目(编号:81503205,81300026);江苏省卫生计生委预防医学科研课题项目(编号:Y2015068);苏州市科技局应用基础研究医疗卫生项目(编号:SYS201541);百特生物药学基金课题(编号:201514);苏州科技局常州四药科研项目(编号:SYSDZ016147)
摘    要:目的:对不同规格布地奈德/福莫特罗吸入剂治疗哮喘患者进行疗效与经济学评价,评估药师在提高吸入装置依从性中的作用。方法:将52例中重度哮喘患者随机分成A、B 2组,分别吸入布地奈德/福莫特罗(160/4.5 μg)每次2吸,bid,及布地奈德/福莫特罗(320/9 μg)每次1吸,bid,治疗时间为12周。分别于第0周、4周和12周,观察哮喘控制测试问卷(asthma control test,ACT)评分和不良反应发生情况,以评价2组的疗效和安全性;统计治疗期间产生的医疗费用做成本分析;对患者吸入装置操作步骤进行干预,并采用问卷形式进行吸入装置依从性评价。结果:治疗前后相比,2组患者ACT评分获得了显著改善;A组和B组的不良反应发生率分别为26.92%和23.08%;而B 组12周人均每日治疗费用更低;经过药师的干预后,2组患者装置依从性显著提高。结论:布地奈德/福莫特罗(320/9 μg)成本-效果比最低,是治疗中重度哮喘的最佳选择。药师在提高哮喘患者吸入装置依从性过程中发挥重要作用。

关 键 词:布地奈德/福莫特罗吸入剂  哮喘  依从性  经济学  
收稿时间:2016-06-06

Economic and device adherence evaluation of different doses of budesonide and formoterol inhalant on patients with asthma
QIN Qiong,SONG Wei-hua,LEI Wei,GONG Yin-hua,MIAO Li-yan,BAO Jian-an,GU Bao-chen,CHEN Rong.Economic and device adherence evaluation of different doses of budesonide and formoterol inhalant on patients with asthma[J].Chinese Journal of Hospital Pharmacy,2016,36(24):2202-2205.
Authors:QIN Qiong  SONG Wei-hua  LEI Wei  GONG Yin-hua  MIAO Li-yan  BAO Jian-an  GU Bao-chen  CHEN Rong
Affiliation:1. Department of Pharmacy, First Affiliated Hospital of Soochow University, Jiangsu Suzhou 215006, China; 2. Department of Respiratory Diseases, First Affiliated Hospital of Soochow University, Jiangsu Suzhou 215006, China
Abstract:OBJECTIVE To perform therapeutic and economic evaluations on budesonide and formoterol inhalant at of different doses in patients with asthma,and evaluate the role of pharmacists in improving patient adherence with drug inhaler.METHODS Fifty two patients with moderate to severe asthma were randomly divided into two groups.Patients took budesonide and formoterol (160/4.5 μg) at two inhalations each time,twice daily in group A,and budesonide and formoterol (320/9 μg) at one inhalation each time, twice daily in group B. Patients in both groups were treated for 12 weeks.At 0,4 and 12 weeks,asthma control test (ACT) scores and adverse reactions were observed to evaluate the efficacy and safety.Medical expenses were analyzed for cost.Adherence with drug inhaler device was evaluated by questionnaires.RESULTS ACT scores of two groups were significantly improved compared to those before treatment.The incidences of adverse reactions of group A and group B were 26.92% and 23.08%,respectively.The mean daily therapy cost of group B during 12 weeks was lower.After intervention by pharmacists,device adherence of two groups was significantly increased.CONCLUSION Budesonide and formoterol (320/9 μg) show a lower cost-effectiveness ratio,and it is the best treatment option for patients with moderate and severe asthma.Pharmacist may play an important role in improving inhaler device adherence in patients with asthma.
Keywords:budesonide and formoterol inhalant  asthma  adherence  economic  
点击此处可从《中国医院药学杂志》浏览原始摘要信息
点击此处可从《中国医院药学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号